UCLA researchers in the Department of Molecular and Medical Pharmacology have discovered that Coenzyme A is a targetable requirement for anti-inflammatory macrophage differentiation.
A dysregulated immune response is a hallmark of many disease phenotypes. For instance, cancer cells can reprogram healthy cells of the innate immune cells to work in conjunction to promote cancer cell growth. There are currently a number of methods being explored to combat this reprogramming, though these methods have shown limited success. There exists an unmet need for a therapy that relies on naturally-occurring bodily substances to help combat this reprogramming either on its own or in conjunction with current standard-of-care cancer treatments such as chemotherapy.
Drs. Divakaruni and Bensinger at UCLA have discovered that Coenzyme-A (CoA) is a targetable requirement for anti-inflammatory macrophage differentiation. This discovery provides a potential point of targeting for macrophage differentiation in cancer models. The identification of CoA as a target for macrophage differentiation can also be used as a point of therapy for many other diseases where an excessive anti-inflammatory response can be causative of pathology (e.g. fibrotic disease, NASH/NAFLD, etc.).
Immune Response, Cancer, Inflammation, Parasitic Infections, Diet induced obesity, Sepsis, Rheumatoid Arthritis, Eczemas, Dermatitis, inflammatory eye disease, fatty liver disease, hepatic steatosis, pulmonary fibrosis, Coenzyme-A, Natural Target